Progress of long-acting interferon in Philadelphia chromosome-negative myloproliferative neoplasms / 白血病·淋巴瘤

ABSTRACT

Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) is a group of chronic hematological tumors caused by clonal proliferation of hematopoietic stem cells, and hydroxyurea is the traditional first-line chemotherapy drug for it. In recent years, pegylated interferon has shown great advantages in the clinical treatment of MPN, and it has become the first-line preferred therapeutic regimen for special populations, especially for young patients and pregnant women.